SCHEMBL3192118

SCHEMBL3192118

COC(=O)c1c(Cl)sc2ccccc12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.69
MAPK1 P28482 1/20 0.69
L3MBTL1 Q9Y468 4/20 0.57
TDP1 Q9NUW8 2/20 0.57
ATM Q13315 2/20 0.57
NPC1 O15118 1/20 0.55
ALDH1A1 P00352 4/20 0.54
MAPT P10636 2/20 0.54
NR4A2 P43354 2/20 0.54
KDM4E B2RXH2 2/20 0.54
HSD17B10 Q99714 2/20 0.54
HPGD P15428 2/20 0.54
MEN1 O00255 1/20 0.54
GLA P06280 1/20 0.54
GAA P10253 1/20 0.54
ALOX15 P16050 1/20 0.54
KMT2A Q03164 1/20 0.54
HDAC1 Q13547 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3599532 0.81 LMNA (0.71) LMNAMAPK1L3MBTL1TDP1ATM
SCHEMBL9495325 0.81 LMNA (1.00) LMNAMAPK1L3MBTL1TDP1ATM
SCHEMBL6656348 0.80 LMNA (0.69) LMNAMAPK1L3MBTL1TDP1ATM
SCHEMBL2721044 0.79 MCL1 (0.49) LMNAMAPK1NPC1ALDH1A1MAPT
SCHEMBL8666781 0.79 MCL1 (0.58) LMNAMAPK1NPC1ALDH1A1KDM4E
SCHEMBL25904738 0.79 LMNA (0.82) LMNAMAPK1L3MBTL1TDP1ATM
SCHEMBL4386528 0.77 LMNA (0.69) LMNAMAPK1ATMNPC1ALDH1A1
SCHEMBL19140605 0.76 LMNA (0.63) LMNAMAPK1L3MBTL1TDP1ATM
SCHEMBL6654580 0.76 LMNA (0.63) LMNAMAPK1L3MBTL1TDP1ATM
SCHEMBL15700049 0.76 LMNA (0.63) LMNAMAPK1L3MBTL1TDP1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7674822-B2 protein tyrosine phosphatase 1B (PTP1B) modulators; type 2 diabetes, obesity; increasing insulin sensitivity; 1-Carboxymethoxy-3,8-dithia-cyclopenta[a]indene-2-carboxylic acid WYETH (US) 2010-03-09 US disclosed
US-20060135488-A1 protein tyrosine phosphatase 1B (PTP1B) modulators; type 2 diabetes, obesity; increasing insulin sensitivity; 1-Carboxymethoxy-3,8-dithia-cyclopenta[a]indene-2-carboxylic acid WYETH 2006-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135488-A1 protein tyrosine phosphatase 1B (PTP1B) modulators; type 2 diabetes, obesity; increasing insulin sensitivity; 1-Carboxymethoxy-3,8-dithia-cyclopenta[a]indene-2-carboxylic acid PTPA, PTPRCAP, PTPRC LMNA 4747/4885MAPK1 403/4885L3MBTL1 3857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.